出版物 打印 Johnson PW, Kunze KL, Senefeld JW, Sinclair JE, Isha S, Satashia PH, Bhakta S, Cowart JB, Bosch W, O'Horo J, Shah SZ, Wadei HM, Edwards MA, Pollock BD, Edwards AJ, Scheitel-Tulledge S, Clune CG, Hanson SN, Arndt R, Heyliger A, Kudrna C, Bierle DM, Buckmeier JR, Seville MTA, Orenstein R, Libertin C, Ganesh R, Franco PM, Razonable RR, Carter RE, Sanghavi DK, Speicher LL. Association of Neutralizing Antispike Monoclonal Antibody Treatment With Coronavirus Disease 2019 Hospitalization and Assessment of the Monoclonal Antibody Screening Score. Mayo Clin Proc Innov Qual Outcomes. 2023 Apr; 7 (2):109-121 Epub 2023 Jan 11 View PubMed Fraker JL, Clune CG, Sahni SK, Yaganti A, Vegunta S. Prevalence, Impact, and Diagnostic Challenges of Benign Breast Disease: A Narrative Review. Int J Womens Health. 2023; 15:765-778 Epub 2023 May 18 View PubMed Razonable RR, O'Horo JC, Challener DW, Arndt L, Arndt RF, Clune CG, Culbertson TL, Hall ST, Heyliger A, Jackson TA, Kennedy BD, Larsen J, Hanson SN, Sweeten PW, Tulledge-Scheitel SM, Ganesh R. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019. Mayo Clin Proc. 2022 Sep; 97 (9):1641-1648 Epub 2022 June 23 View PubMed Bierle DM, Ganesh R, Tulledge-Scheitel S, Hanson SN, Arndt LL, Wilker CG, Razonable RR. Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities. J Infect Dis. 2022 Feb 15; 225 (4):598-602 View PubMed O'Horo JC, Challener DW, Speicher L, Bosch W, Seville MT, Bierle DM, Ganesh R, Wilker CG, Arndt RF, Arndt LL, Tulledge-Scheitel SM, Hanson SN, Razonable RR. Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant. Mayo Clin Proc. 2022 Feb; 97 (2):327-332 Epub 2021 Dec 16 View PubMed Wilker CG, Stockham AL, Houge BJ, Stevens SK, Munson KA, Mueller PS. Computer-Based Patient Bias and Misconduct Training Impact on Reports to Incident Learning System. Mayo Clin Proc Innov Qual Outcomes. 2021 Dec; 5 (6):1075-1080 Epub 2021 Nov 14 View PubMed Ganesh R, Philpot LM, Bierle DM, Anderson RJ, Arndt LL, Arndt RF, Culbertson TL, Destro Borgen MJ, Hanson SN, Kennedy BD, Kottke BB, Larsen JJ, Ramar P, Rosedahl JK, Seville MT, Speicher LL, Tulledge-Scheitel SM, Wilker CG, Razonable RR. Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019. J Infect Dis. 2021 Oct 28; 224 (8):1278-1286 View PubMed Razonable RR, Pawlowski C, O'Horo JC, Arndt LL, Arndt R, Bierle DM, Borgen MD, Hanson SN, Hedin MC, Lenehan P, Puranik A, Seville MT, Speicher LL, Tulledge-Scheitel SM, Venkatakrishnan AJ, Wilker CG, Badley AD, Ganesh R. Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. EClinicalMedicine. 2021 Oct; 40:101102 Epub 2021 Aug 30 View PubMed Ganesh R, Pawlowski CF, O'Horo JC, Arndt LL, Arndt RF, Bell SJ, Bierle DM, Borgen MD, Hanson SN, Heyliger A, Larsen JJ, Lenehan PJ, Orenstein R, Puranik A, Speicher LL, Tulledge-Scheitel SM, Venkatakrishnan AJ, Wilker CG, Badley AD, Razonable RR. Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19. J Clin Invest. 2021 Oct 1; 131 (19) View PubMed Bierle DM, Croghan IT, Ganesh R, Wilker CG, Hanson S, Moehnke DE, Jackson TA, Ramar P, Rosedahl JK, Philpot L, Razonable RR. Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19 Journal of Primary Care and Community Health. 2021. Razonable RR, Aloia NCE, Anderson RJ, Anil G, Arndt LL, Arndt RF, Ausman SE, Bell SJ, Bierle DM, Billings ML, Bishop RK, Cramer CH, Culbertson TL, Dababneh AS, Derr AN, Epps K, Flaker SM, Ganesh R, Gilmer MA, Urena EG, Gulden CR, Haack TL, Hanson SN, Herzog JR, Heyliger A, Hokanson LD, Hopkins LH, Horecki RJ, Krishna BH, Huskins WC, Jackson TA, Johnson RR, Jorgenson B, Kudrna C, Kennedy BD, Klingsporn MK, Kottke B, Larsen JJ, Lessard SR, Lutwick LI, Malone EJ 3rd, Matoush JA, Micallef IN, Moehnke DE, Mohamed M, Ness CN, Olson SM, Orenstein R, Palraj R, Patel J, Paulson DJ, Phelan D, Peinovich MT, Ramsey WL, Rau-Kane TJ, Reid KI, Reinschmidt KJ, Seville MT, Skold EC, Smith JM, Speicher LL, Spielman LA, Springer DJ, Sweeten PW, Tempelis JM, Tulledge-Scheitel S, Vergidis P, Whipple DC, Wilker CG, Destro Borgen MJ. A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model. Mayo Clin Proc. 2021 May; 96 (5):1250-1261 Epub 2021 Mar 09 View PubMed Bierle DM, Ganesh R, Wilker CG, Hanson SN, Moehnke DE, Jackson TA, Ramar P, Rosedahl JK, Philpot LM, Razonable RR. Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19. J Prim Care Community Health. 2021 Jan-Dec; 12:21501327211019282 View PubMed PST-20527356 主页 出版物